# Pegfilgrastim

## Fulphila inj 6mg/0.6mL

| TAH Drug Code      | [IFUL](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IFUL)                                                                                                                                                                                                                                               |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | To decrease the incidence of infection， as manifested by febrile neutropenia， in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.                                                                  |
| Dosing             | Patients with cancer receiving myelosuppressive chemotherapy: 6 mg subQ once per chemotherapy cycle. Do not administer between 14 days before and 24 hours after administration of cytotoxic chemotherapy.                                                                                                         |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                      |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                      |
| Contraindications  | Individuals allergic to latex should not use this product. Fulphila is contraindicated in patients with a history of severe hypersensitivity reactions to pegfilgrastim or filgrastim， including anaphylaxis. Acute respiratory distress syndrome (ARDS).                                                         |
| Adverse Effects    | Common: Bone pain (31%)， Pain in limb (9%) Serious: Aortitis， Capillary leak syndrome， Acute myeloid leukemia， Leukocytosis (<1% )， Myelodysplastic syndrome， Rupture of spleen， Sickle cell anemia with crisis， Thrombocytopenia， Anaphylaxis， Glomerulonephritis， Acute respiratory distress syndrome |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                             |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                      |
| More Info          | [UpToDate](https://www.uptodate.com/contents/pegfilgrastim-drug-information)                                                                                                                                                                                                                                       |

